Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Electronic monitoring of antiretroviral adherence in "real time" boosts pill taking and need for intensive adherence support

Electronic monitoring of antiretroviral adherence in “real time” significantly increases the proportion of treatment doses taken on time and reduces the frequency of treatment interruptions, according to a

Published
05 December 2016
By
Michael Carter
Top 10 HIV Clinical Developments of 2016

In typical years, a noteworthy development in the world of HIV would be the result of a landmark clinical trial or perhaps a gem of a lab study with a novel finding. But, 2016 was not typical. What made the most difference for people living with HIV and their health care providers this past year was less a paper published or presented than major shifts in our thinking about how best to prevent and manage HIV infection.

Published
02 December 2016
From
The Body Pro
Ending the HIV epidemic faces daunting barriers, former WHO HIV chief warns

The difficulty of bringing the HIV epidemic “down to zero” should not be underestimated, Kevin de Cock, former director of HIV for the World Health Organization (WHO),

Published
30 November 2016
By
Gus Cairns
Behavioral Therapy Provides Depression and Adherence Benefits in HIV Study

Four months of cognitive behavioral therapy for depression and antiretroviral adherence significantly improved adherence and depression scores when compared with treatment as usual in a three-way randomized trial involving adults with HIV infection. Relative improvements in adherence and depression held up in the eight months after the interventions ended.

Published
30 November 2016
From
The Body Pro
China to approve 1st long-acting injection to treat HIV/AIDS

China's national drug authority on Wednesday examined clinical research results on a domestically produced anti-HIV drug in its final phase prior to officially approving the drug. Once approved, the new-generation drug, named Albuvirtide for Injection, is expected to be the world's first long-acting injection for HIV treatment.

Published
25 November 2016
From
Global Times
Kiwi HIV patients 'denied access to medication'

The New Zealand AIDS Foundation (NZAF) says Kiwis with newly diagnosed HIV infections are being unfairly penalised by outdated policies denying them access to important medication. Currently people diagnosed with HIV in New Zealand cannot access medication until their CD4 cell (white blood cell) count has dropped below 500.

Published
24 November 2016
From
Newshub
What's at Stake in Trump's America? HIV Community Leaders Share Their Opinions

By Election Day Nov. 8, after an eventful primary season and a noxious election cycle, it seemed that most HIV advocates were ready to get to work with a soon-to-be President-elect Hillary Clinton's soon-to-be administration, to continue the pioneering work activists forged under President Obama in addressing HIV in the U.S. Then the unthinkable happened. In the wee hours of Nov. 9, Donald J. Trump was declared the president-elect of the United States.

Published
21 November 2016
From
The Body
ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen

Studies will investigate monthly dosing with injectable cabotegravir and rilpivirine

Published
21 November 2016
From
ViiV press release
Exposed: Southern African trio 'sold expired ARVs' in Europe at a 4 000% markup

Life-saving HIV drugs were allegedly diverted from Africa's public health system to sell in Europe.

Published
17 November 2016
From
Bhekisisa
NIH Scientists Identify Potent Antibody that Neutralizes Nearly All HIV Strains

Scientists from the National Institutes of Health have identified an antibody from an HIV-infected person that potently neutralized 98 percent of HIV isolates tested, including 16 of 20 strains resistant to other antibodies of the same class. The remarkable breadth and potency of this antibody, named N6, make it an attractive candidate for further development to potentially treat or prevent HIV infection, say the researchers.

Published
17 November 2016
From
National Institute of Allergy and Infectious Diseases
← First12345...431Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.